Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Nucala® (mepolizumab) – New orphan indication
December 12, 2017 – The FDA announced the approval of GlaxoSmithKline’s Nucala (mepolizumab) for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).
